Moody’s Is Bullish on Pharma Industry for Next 18 Months

The pharmaceutical industry should continue to enjoy strong financial results in the next 12 to 18 months, according to a new report from Moody’s Investors Service. The credit ratings firm projects 4% to 6% growth in annual earnings before interest, taxes, depreciation and amortization over that period.

The authors predict that growth will be driven by increased uptake of oncology, immunology and diabetes drugs; COVID-19 vaccines and boosters; and a low number of patents set to expire. However, the report does project some headwinds for pharmaceutical firms, namely potential drug pricing legislation and increased biosimilar development. The report also predicted that “pharmaceutical spending will continue to rise globally, across almost all regions.”

© 2023 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

bills-and-pills
January 26

Medicare Enrollees May Still Face Affordability Issues After Part D Benefit Redesign

READ MORE
pills-in-hand
January 26

ICER Report Aims to Nudge Payers Toward Fairer Drug Coverage Policies

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
January 26

News Briefs: Lilly Alzheimer’s Drug Fails to Win Accelerated Approval

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today